Advertisement

Epidemiology of Blood Lipids and Lipoproteins

  • Peter W.F. WilsonEmail author
Chapter
Part of the Contemporary Endocrinology book series (COE)

Abstract

Cholesterol levels in adults are related to several lifestyle factors, including obesity, cigarette smoking, ethanol intake, and physical activity. Higher levels generally confer greater risk for cardiovascular disease (CVD) events. The key determinants for higher levels of atherogenic lipids measured as low-density lipoprotein cholesterol (LDL-C) include high dietary saturated fat, high dietary cholesterol, and low dietary polyunsaturated fat. The key determinants of low high-density lipoprotein cholesterol (HDL-C), which is associated with greater CVD risk, include male sex, androgen use, progestin use, estrogen deficiency, adiposity, cigarette use, low alcohol intake, diabetes mellitus, and low dietary saturated fat. Mean cholesterol levels have generally risen in the past several decades in regions around the world where the economy is developing. On the other hand, in the developed regions of the world such as the USA and Western Europe, mean cholesterol levels in adults have generally stayed the same or declined modestly.

Keywords

Coronary heart disease Risk factor Cholesterol Triglycerides Cardiovascular disease 

References

  1. 1.
    Kannel WB, McGee DL. Diabetes and cardiovascular risk factors: the Framingham Study. Circulation. 1979;59:8–13.CrossRefPubMedGoogle Scholar
  2. 2.
    Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, Shih J, Stamler J, Wentworth D. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:1490–500.CrossRefPubMedGoogle Scholar
  3. 3.
    Stamler J, Wentworth DN, Neaton JD. Is the relationship between serum cholesterol and risk of death from coronary heart disease continuous and graded? Findings on the 356,222 primary screenees of the Multiple Risk Factor Interventional Trial (MRFIT). JAMA. 1986;256:2823–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16(2):434–44.CrossRefPubMedGoogle Scholar
  5. 5.
    Dyer AR, Stamler J, Paul O, Shekelle RB, Schoenberger JA, Berkson DM, Lepper M, Collette P, Shekelle S, Lindberg HA. Serum cholesterol and risk of death from cancer and other causes in three Chicago epidemiological studies. J Chronic Dis. 1981;34:249.CrossRefPubMedGoogle Scholar
  6. 6.
    Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J III. Factors of risk in the development of coronary heart disease—six year follow-up experience. The Framingham Study. Ann Intern Med. 1961;55:33–50.CrossRefPubMedGoogle Scholar
  7. 7.
    Shekelle RB, Stamler J, Paul O, Shyrock AM, Liu S, Lepper M. Dietary lipids and serum cholesterol level: Change in diet confounds the cross-sectional association. Am J Epidemiol. 1982;115:506–14.PubMedGoogle Scholar
  8. 8.
    Verschuren WM, Jacobs DR, Bloemberg BP, Kromhout D, Menotti A, Aravanis C, Blackburn H, Buzina R, Dontas AS, Fidanza F. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five-year follow-up of the seven countries study. JAMA. 1995;274:131–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Lloyd-Jones DM, Wilson PW, Larson MG, Leip E, Beiser A, D’Agostino RB, Cleeman JI, Levy D. Lifetime risk of coronary heart disease by cholesterol levels at selected ages. Arch Intern Med. 2003;163(16):1966–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321–9. (PMCID:PMC3336876).CrossRefPubMedCentralPubMedGoogle Scholar
  11. 11.
    Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins—an integrated approach to mechanisms and disorders. N Engl J Med. 1967;276:94–103.CrossRefPubMedGoogle Scholar
  12. 12.
    Heiss G, Tamir I, Davis CE, Tyroler HA, Rifkind BM, Schonfeld G, Jacobs DR Jr, Frantz ID Jr. Lipoprotein-cholesterol distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation. 1980;61:302–15.CrossRefPubMedGoogle Scholar
  13. 13.
    Brensike JF, Levy RI, Kelsey SF, Passamani ER, Richardson JM, Loh IK, Stone NJ, Aldrich RF, Battaglini JW, Moriarty DJ, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II coronary intervention study. Circulation. 1984;69:313–24.CrossRefPubMedGoogle Scholar
  14. 14.
    Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med. 1977;62:707–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischemic heart disease. Lancet. 1975;1:16–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Coronary heart disease incidence and lipoprotein cholesterol levels: the Framingham Study. JAMA. 1986;256:2835–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Wilson PWF, Abbott RD, Kannel WB, Castelli WP. High density lipoprotein cholesterol and mortality: The Framingham Study. Arteriosclerosis. 1988;8:737–41.CrossRefPubMedGoogle Scholar
  18. 18.
    Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham Study. Arteriosclerosis. 1988;8(3):207–11.CrossRefPubMedGoogle Scholar
  19. 19.
    Keys A, Anderson JT, Grande F. Serum cholesterol response to changes in the diet. II. The effect of cholesterol in the diet. Metabolism. 1965;14:749–65.CrossRefGoogle Scholar
  20. 20.
    Gardner CD, Kraemer HC. Monounsaturated versus polyunsaturated dietary fat and serum lipids. A meta-analysis. Arterioscler Thromb Vasc Biol. 1995;15(11):1917–27.CrossRefPubMedGoogle Scholar
  21. 21.
    Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest. 2003;111(12):1795–803.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Steyn K, Fourie JM, Shepherd J. Detection and measurement of hypercholesterolaemia in South Africans attending general practitioners in private practice—the cholesterol monitor. S Afr Med J. 1998;88(12):1569–74.PubMedGoogle Scholar
  23. 23.
    Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman’s lifetime. Am J Obstet Gynecol. 1988;158:1630–43.CrossRefPubMedGoogle Scholar
  24. 24.
    Vaziri SM, Evans JC, Larson MG, Wilson PWF. The impact of female hormone usage on the lipid profile: the Framingham Offspring Study. Arch Intern Med. 1993;153:2200–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Garrison RJ, Wilson PW, Castelli WP, Feinleib M, Kannel WB, McNamara PM. Obesity and lipoprotein cholesterol in the Framingham offspring study. Metabolism. 1980;29(11):1053–60.CrossRefPubMedGoogle Scholar
  26. 26.
    Lamon-Fava S, Jimenez D, Fabsitz RR, Reed T, Carmelli D, Castelli WP, Ordovas JM, Wilson PWF, Schaefer EJ. The NHLBI Twin Study: heritability of apolipoprotein A-I, B, and low density lipoprotein subclasses and condordance for lipoprotein (a). Atherosclerosis. 1991;91:97–106.CrossRefPubMedGoogle Scholar
  27. 27.
    Anderson KM, Wilson PWF, Garrison RJ, Castelli WP. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample: the Framingham Offspring Study. Atherosclerosis. 1987;68:59–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Campos H, Wilson PWF, Jimenez D, McNamara JR, Ordovas J, Schaefer EJ. Differences in apolipoproteins and low-density lipoprotein subfractions in postmenopausal women on and off estrogen therapy: results from the Framingham Offspring Study. Metabolism. 1990;39:1033–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Dannenberg AL, Keller JB, Wilson PWF, Castelli WP. Leisure time physical activity in the Framingham Offspring Study. Description, seasonal variation, and risk factor correlates. Am J Epidemiol. 1989;129:76–87.PubMedGoogle Scholar
  30. 30.
    Williams PT, Haskell WL, Vranizan KM, Krauss RM. The associations of high-density lipoprotein subclasses with insulin and glucose levels, physical activity, resting heart rate, and regional adiposity in men with coronary artery disease: the Stanford Coronary Risk Intervention Project baseline survey. Metabolism. 1995;44(1):106–14.CrossRefPubMedCentralPubMedGoogle Scholar
  31. 31.
    Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 1991;325:461–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, et al. Effects of the amount and intensity of exercise on plasma lipoproteins. N Engl J Med. 2002;347(19):1483–92.CrossRefPubMedGoogle Scholar
  33. 33.
    Durrington P. Dyslipidaemia. Lancet. 2003;362(9385):717–31.CrossRefPubMedGoogle Scholar
  34. 34.
    Brunzell JD, Schrott HG, Motulsky AG, et al. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism. 1976;25:313–20.CrossRefPubMedGoogle Scholar
  35. 35.
    Siegel RD, Cupples A, Schaefer EJ, Wilson PW. Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham offspring study. Metabolism. 1996;45(10):1267–72.CrossRefPubMedGoogle Scholar
  36. 36.
    Garrison RJ, Kannel WB, Feinleib M, Castelli WP, McNamara PM, Padgett SJ. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis. 1978;30(1):17–25.CrossRefPubMedGoogle Scholar
  37. 37.
    Mukamal KJ, Jadhav PP, D’Agostino RB, Massaro JM, Mittleman MA, Lipinska I, Sutherland PA, Matheney T, Levy D, Wilson PW, et al. Alcohol consumption and hemostatic factors: analysis of the Framingham Offspring cohort. Circulation. 2001;104(12):1367–73.CrossRefPubMedGoogle Scholar
  38. 38.
    Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW, D’Agostino RB, et al. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. JAMA. 2007;298(7):776–85.CrossRefPubMedGoogle Scholar
  39. 39.
    Freedman DS, Otvos JD, Jeyarajah EJ, Shalaurova I, Cupples LA, Parise H, D’Agostino RB, Wilson PW, Schaefer EJ. Sex and age differences in lipoprotein subclasses measured by nuclear magnetic resonance spectroscopy: the Framingham Study. Clin Chem. 2004;50(7):1189–200.CrossRefPubMedGoogle Scholar
  40. 40.
    Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA, Schaefer EJ. Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA. 1994;272(21):1666–71.CrossRefPubMedGoogle Scholar
  41. 41.
    Cromwell W, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Wilson PWF, D’Agostino RB Sr. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study–Implications for LDL management. J Clin Lipidol. 2007;1:583–92.CrossRefPubMedCentralPubMedGoogle Scholar
  42. 42.
    Wilson PW, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation. 2005;112(20):3066–72.CrossRefPubMedGoogle Scholar
  43. 43.
    Meigs JB, Rutter MK, Sullivan LM, Fox CS, D’Agostino RB Sr, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care. 2007;30(5):1219–25.CrossRefPubMedGoogle Scholar
  44. 44.
    McNamara JR, Campos H, Ordovas JM, Peterson J, Wilson PWF, Schaefer EJ. Effect of gender, age, and lipid status on low density lipoprotein subfraction distribution: results from the Framingham Offspring Study. Arteriosclerosis. 1987;7:483–90.CrossRefPubMedGoogle Scholar
  45. 45.
    Campos H, McNamara JR, Wilson PWF, Ordovas JM, Schaefer EJ. Differences in low density lipoprotein subfractions and apolipoproteins in premenopausal and postmenopausal women. J Clin Endo Metab. 1988;67:30–5.CrossRefGoogle Scholar
  46. 46.
    Meigs JB, Mittleman MA, Nathan DM, Tofler GH, Singer DE, Murphy-Sheehy PM, Lipinska I, D’Agostino RB, Wilson PW. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA. 2000;283(2):221–8..Google Scholar
  47. 47.
    Meigs JB, Jacques PF, Selhub J, Singer DE, Nathan DM, Rifai N, D–Agostino RB, Wilson PW. Fasting plasma homocysteine levels in the insulin resistance syndrome: the Framingham offspring study. Diabetes Care. 2001;24(8):1403–10.Google Scholar
  48. 48.
    Hivert MF, Sullivan LM, Fox CS, Nathan DM, D’Agostino RB Sr, Wilson PW, Meigs JB. Associations of adiponectin, resistin, and tumor necrosis factor-alpha with insulin resistance. J Clin Endocrinol Metab. 2008;93(8):3165–72. (PMCID:PMC2515087).CrossRefPubMedCentralPubMedGoogle Scholar
  49. 49.
    Bostom AG, Gagnon DR, Cupples LA, Wilson PWF, Jenner JL, Ordovas JM, Schaefer EJ, Castelli WP. A prospective investigation of elevated lipoprotein (a) detected by electrophoresis and cardiovascular disease in women: the Framingham Heart Study. Circulation. 1994;90:1688–95.CrossRefPubMedGoogle Scholar
  50. 50.
    Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. JAMA. 1996;276:544–8.CrossRefPubMedGoogle Scholar
  51. 51.
    Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet. 2001;358(9298):2026–33.CrossRefPubMedGoogle Scholar
  52. 52.
    Barter PJ, Ballantyne CM, Carmena R, Castro CM, Chapman MJ, Couture P, de Graaf J, Durrington PN, Faergeman O, Frohlich J, et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med. 2006;259(3):247–58.CrossRefPubMedGoogle Scholar
  53. 53.
    Scanu AM, Scandiani L. Lipoprotein(a): structure, biology and clinical relevance. Adv Intern Med. 1991;36:249–70.PubMedGoogle Scholar
  54. 54.
    Austin MA, Hokanson JE, Brunzell JD. Characterization of low-density lipoprotein subclasses: methodologic approaches and clinical relevance. Curr Opinion Lipid. 1994;5(6):395–403.CrossRefGoogle Scholar
  55. 55.
    Myers RH, Schaefer EJ, Wilson PWF, D’Agostino RB, Bachman DL, Ordovas JM, Au R, Cobb JL, Wolf PA. Apolipoprotein E allele 4 is associated with dementia in the Framingham Study. In: Iqbal K, Mortimer JA, Winblad B, et al., editors. Research advances in Alzheimer’s disease and related disorders. 1st ed. Wiley; 1995. pp. 63–70.Google Scholar
  56. 56.
    Myers RH, Schaefer EJ, Wilson PWF, D’Agostino RB, Ordovas JM, Espino A, Au R, White RF, Knoefel JE, Cobb JL, et al. Apolipoprotein E allele 4 is asociated with dementia in a population based study: the Framingham Study. Neurology. 1996;46:673–7.CrossRefPubMedGoogle Scholar
  57. 57.
    Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358(12):1240–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Kathiresan S, Musunuru K, Orho-Melander M. Defining the spectrum of alleles that contribute to blood lipid concentrations in humans. Curr Opin Lipidol. 2008;19(2):122–7.CrossRefPubMedGoogle Scholar
  59. 59.
    Kathiresan S, Melander O, Guiducci C, Surti A, Burtt NP, Rieder MJ, Cooper GM, Roos C, Voight BF, Havulinna AS, et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet. 2008;40(2):189–97.CrossRefPubMedCentralPubMedGoogle Scholar
  60. 60.
    Cupples LA, Arruda HT, Benjamin EJ, D’Agostino RB Sr, Demissie S, DeStefano AL, Dupuis J, Falls KM, Fox CS, Gottlieb DJ, et al. The Framingham Heart Study 100K SNP genome-wide association study resource: overview of 17 phenotype working group reports. BMC Med Genet. 2007;8(Suppl 1):S1.Google Scholar
  61. 61.
    Humphries SE, Norbury G, Leigh S, Hadfield SG, Nair D. What is the clinical utility of DNA testing in patients with familial hypercholesterolaemia? Curr Opin Lipidol. 2008;19(4):362–8.CrossRefPubMedGoogle Scholar
  62. 62.
    Wilson PW, D’Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–47.CrossRefPubMedGoogle Scholar
  63. 63.
    Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile. A statement for health professionals. Circulation. 1991;83:357–63.Google Scholar
  64. 64.
    Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–8.CrossRefPubMedGoogle Scholar
  65. 65.
    Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118(25):2702–9.CrossRefPubMedCentralPubMedGoogle Scholar
  66. 66.
    McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volkova E, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–33.CrossRefPubMedGoogle Scholar
  67. 67.
    Wolf PA, D’Agostino RB, Belanger AJ, Kannel WB. Probability of stroke: a risk profile from the Framingham Study. Stroke. 1991;3:312–8.CrossRefGoogle Scholar
  68. 68.
    Wilson PWF, Hoeg JM, D’Agostino RB, Silbershatz H, Belanger AM, Poehlmann H, O’Leary D, Wolf PA. Cumulative effects of high cholesterol levels, high blood pressure, and cigarette smoking on carotid stenosis. N Engl J Med. 1997;337(8):516–22.CrossRefPubMedGoogle Scholar
  69. 69.
    Lamon-Fava S, Wilson PW, Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 1996;16(12):1509–15.CrossRefPubMedGoogle Scholar
  70. 70.
    Meigs JB, D’Agostino RB, Wilson PWF, Cupples LA, Nathan DM, Singer DE. Risk variable clustering in the insulin resistance syndrome. Diabetes. 1997;46:1594–600.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press 2015

Authors and Affiliations

  1. 1.Medicine and Public HealthEmory UniversityAtlantaUSA

Personalised recommendations